Greenspan, Susan L <br/><br/>
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.  [electronic resource] 

 -  Annals of internal medicine  Dec 2002 
 - 875-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1539-3704 
<br/><br/><label>Standard No.: </label>10.7326/0003-4819-137-11-200212030-00008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alendronate--adverse effects<br/>Biomarkers--analysis<br/>Bone Density--drug effects<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Estrogen Replacement Therapy--adverse effects<br/>Estrogens, Conjugated (USP)--adverse effects<br/>Female<br/>Hip--physiology<br/>Humans<br/>Lumbar Vertebrae--drug effects<br/>Middle Aged<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Placebos<br/>Treatment Outcome<br/>Withholding Treatment